Preferredregimen forHR+ diseasefor frail/elderlypatientsThe ATLAS,AttOM, MA.17Rtrials evaluatedthis durationbenefit ofendocrine therapyThis subtype ofbreast cancerhas the lowestrelative 5-yearsurvival rate This drug class iscontraindicatedcombined withtrastuzumab-avoid for 7 monthsafter lasttrastuzumab doseDuration of timepatients willtakeabemaciclib inearly stagediseaseThis agent cancauseendometrialcancer, but hasbone densityprotective effectI can give thisagent in highrisk BRCA1/2 mutationfor 1 yearThis prodrug isgiven in TNBC forpatients who do notachieve pathologiccomplete responsebased on CREATE-X trialThis agent is notused inpremenopausalwomen as endocrinetherapy unless theyalso receive ovariansuppression This agent canbe added toLN+ HER2+disease givenwithtrastuzumabThis agentshould beinitiated withneratinib for thefirst 8 weeksThis agent iswell studied fortamoxifeninduced hotflashes inbreast cancerPatients withHER2+ diseasecontinuetargetedtherapy for thisdurationBased onTAILORx, <50years receivechemoendocrinetherapy if theyhave thisOncotypeDx score Patients who donot achieve pCRin HER2+disease and haveresidual diseaseget this therapyThis CDK 4/6inhibitor is the onlyone in its drugclass also used inearly stage breastcancerUsed asneoadjuvant andadjuvant therapyin high risk TNBCbased on theKEYNOTE 522trialPreferredfrequencyof GnRHagonistsThis should bemonitoredroutinely every3-4 monthswhile receivingtrastuzumab This drugclass are thebackbone ofHR+ disease1%This treatmentmodality isalwayscombined withlumpectomysurgeryThe onlysteroidalaromataseinhibitor in itsdrug classBased onOncotype DX,a score of 35will receivethis treatmentPreferredregimen forHR+ diseasefor frail/elderlypatientsThe ATLAS,AttOM, MA.17Rtrials evaluatedthis durationbenefit ofendocrine therapyThis subtype ofbreast cancerhas the lowestrelative 5-yearsurvival rate This drug class iscontraindicatedcombined withtrastuzumab-avoid for 7 monthsafter lasttrastuzumab doseDuration of timepatients willtakeabemaciclib inearly stagediseaseThis agent cancauseendometrialcancer, but hasbone densityprotective effectI can give thisagent in highrisk BRCA1/2 mutationfor 1 yearThis prodrug isgiven in TNBC forpatients who do notachieve pathologiccomplete responsebased on CREATE-X trialThis agent is notused inpremenopausalwomen as endocrinetherapy unless theyalso receive ovariansuppression This agent canbe added toLN+ HER2+disease givenwithtrastuzumabThis agentshould beinitiated withneratinib for thefirst 8 weeksThis agent iswell studied fortamoxifeninduced hotflashes inbreast cancerPatients withHER2+ diseasecontinuetargetedtherapy for thisdurationBased onTAILORx, <50years receivechemoendocrinetherapy if theyhave thisOncotypeDx score Patients who donot achieve pCRin HER2+disease and haveresidual diseaseget this therapyThis CDK 4/6inhibitor is the onlyone in its drugclass also used inearly stage breastcancerUsed asneoadjuvant andadjuvant therapyin high risk TNBCbased on theKEYNOTE 522trialPreferredfrequencyof GnRHagonistsThis should bemonitoredroutinely every3-4 monthswhile receivingtrastuzumab This drugclass are thebackbone ofHR+ disease1%This treatmentmodality isalwayscombined withlumpectomysurgeryThe onlysteroidalaromataseinhibitor in itsdrug classBased onOncotype DX,a score of 35will receivethis treatment

BC questions - Call List

(Print) Use this randomly generated list as your call list when playing the game. There is no need to say the BINGO column name. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
  1. Preferred regimen for HR+ disease for frail/elderly patients
  2. The ATLAS, AttOM, MA.17R trials evaluated this duration benefit of endocrine therapy
  3. This subtype of breast cancer has the lowest relative 5-year survival rate
  4. This drug class is contraindicated combined with trastuzumab- avoid for 7 months after last trastuzumab dose
  5. Duration of time patients will take abemaciclib in early stage disease
  6. This agent can cause endometrial cancer, but has bone density protective effect
  7. I can give this agent in high risk BRCA 1/2 mutation for 1 year
  8. This prodrug is given in TNBC for patients who do not achieve pathologic complete response based on CREATE-X trial
  9. This agent is not used in premenopausal women as endocrine therapy unless they also receive ovarian suppression
  10. This agent can be added to LN+ HER2+ disease given with trastuzumab
  11. This agent should be initiated with neratinib for the first 8 weeks
  12. This agent is well studied for tamoxifen induced hot flashes in breast cancer
  13. Patients with HER2+ disease continue targeted therapy for this duration
  14. Based on TAILORx, <50 years receive chemoendocrine therapy if they have this OncotypeDx score
  15. Patients who do not achieve pCR in HER2+ disease and have residual disease get this therapy
  16. This CDK 4/6 inhibitor is the only one in its drug class also used in early stage breast cancer
  17. Used as neoadjuvant and adjuvant therapy in high risk TNBC based on the KEYNOTE 522 trial
  18. Preferred frequency of GnRH agonists
  19. This should be monitored routinely every 3-4 months while receiving trastuzumab
  20. This drug class are the backbone of HR+ disease
  21. 1%
  22. This treatment modality is always combined with lumpectomy surgery
  23. The only steroidal aromatase inhibitor in its drug class
  24. Based on Oncotype DX, a score of 35 will receive this treatment